

Item S1. Search strategy algorithms

Search strategy of randomized controlled trials (run on 8/5/2010)

- | | |
|--|--|
| 1. randomized controlled trial.pt. | 35. ur ?emia.af. or ur ?emia.tw. |
| 2. controlled clinical trial.pt. | 36. h?emodialysis.af. or h?emodialysis.tw. |
| 3. randomized controlled trials/ | 37. (hemofiltr\$ or haemofiltr\$).af. or (hemofiltr\$ or haemofiltr\$).tw.38. or/24-37 |
| 4. Random Allocation/ | 39. Animals/ not humans.mp. [mp=ti, ot, ab, nm, hw, ui, sh, kw] |
| 5. Double-blind Method/ | 40. 38 not 39 |
| 6. Single-Blind Method/ | 41. exp anemia/ |
| 7. clinical trial.pt. | 42. exp Hemoglobins/ |
| 8. Clinical Trials.mp. or exp Clinical Trials/ | 43. exp hematocrit/ |
| 9. (clinic\$ adj25 trial\$).tw. | 44. exp Hematologic Tests/ |
| 10. ((singl\$ or doubl\$ or trebl\$ or tripl\$) adj (mask\$ or blind\$)).tw. | 45. exp Anemia, Refractory/ |
| 11. Placebos/ | 46. exp Red-Cell Aplasia, Pure/ |
| 12. placebo\$.tw. | 47. h?emoglobin\$.af. or h?emoglobin\$.tw. |
| 13. random\$.tw. | 48. an?emi\$.af. or an?emi\$.tw. |
| 14. trial\$.tw. | 49. h?ematocrit\$.af. or h?ematocrit\$.tw. |
| 15. (randomized control trial or clinical control trial).sd. | 50. or/41-49 |
| 16. (latin adj square).tw. | 51. exp Erythropoietin/ |
| 17. Comparative Study.tw. or Comparative Study.pt. | 52. exp Erythropoietin, Recombinant/ |
| 18. exp Evaluation studies/ | 53. exp hematinics/ |
| 19. Follow-Up Studies/ | 54. Erythropoietin.af. or Erythropoietin.tw. |
| 20. Prospective Studies/ | 55. (h?ematopietin or h?emopietin).af. or (h?ematopietin or h?emopietin).tw. |
| 21. (control\$ or prospectiv\$ or volunteer\$).tw. | 56. erythrocyte stimulat\$.af. or erythrocyte stimulat\$.tw. |
| 22. Cross-Over Studies/ | 57. (epogen or epotin or betapoeitin or relpoeitin or epokine or procrit or eprex or darbopoeitin).af. or (epogen or epotin or betapoeitin or relpoeitin or epokine or procrit or eprex or darbopoeitin).tw. |
| 23. or/1-22 | 58. (NeoRecormon or Aranesp or Methoxy Polyethylene Glycol Epoetin Beta or MIRCERA or Epoetin or Dynepo or PDpoeitin).af. or (NeoRecormon or Aranesp or Methoxy Polyethylene Glycol Epoetin Beta or MIRCERA or Epoetin or Dynepo or PDpoeitin).tw. |
| 24. exp Kidney Glomerulus/ | 59. or/51-58 |
| 25. exp Kidney disease/ | 60. 59 and (40 and 50 and 23) |
| 26. exp Kidney Function Tests/ | |
| 27. exp Renal Replacement Therapy/ | |
| 28. exp Kidney Transplantation/ | |
| 29. exp kidney, artificial/ | |
| 30. exp ultrafiltration/ | |
| 31. exp sorption, detoxification/ | |
| 32. renal.af. or renal.tw. | |
| 33. nephro\$.af. or nephro\$.tw. | |
| 34. kidney.af. or kidney.tw. | |

Search strategy of meta-analyses (run on June 2010)

" Hematinics "[Mesh] or " erythropoietin "[Mesh] or epogen [All Fields] or epoetin [All Fields] or megapoeitin [All Fields] or rely poeitin [All Fields] or epokine [All Fields] or shan poeitin [All Fields] or procrit [All Fields] or eprex [All Fields] or neorecormon [All Fields] or darbepoeitin [All Fields] or aranesp [All Fields] or epoetin delta [All Fields] or dynamo [All Fields] or pdpoeitin [All Fields] or methoxy polyethylene glycol-epoetin beta [All Fields] or mircera [All Fields] or darbepoeitin alfa [All Fields] or epoetin alfa [All Fields] or cera [All Fields] or Continuous erythropoietin receptor activator AND "Meta-Analysis "[Publication Type]